A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 290
- 试验地点
- 1
- 主要终点
- Response to treatment
研究概览
简要总结
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be an effective treatment for liver cancer.
详细描述
PRIMARY OBJECTIVES:
I. Provide oversight to treatment with TheraSphere to eligible patients with hepatocellular carcinoma (HCC) of the liver who are not surgical resection candidates.
II. Evaluate patient experience, toxicities and overall survival associated with TheraSphere treatment.
OUTLINE:
Patients receive yttrium Y 90 glass microspheres intra-arterially (IA) on day 0, and may receive a second dose within 30-90 days of initial treatment. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of intrahepatic malignancy including but not limited to HCC; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alpha-fetoprotein (AFP) and clinical findings
- •Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2
- •Life expectancy >= 3 months
- •> 4 weeks since prior radiation, surgery or chemotherapy
- •Able to comprehend and provide written informed consent in accordance with institutional and federal guidelines
- •Ineligible for surgical resection
排除标准
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (UNL)
- •Serum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)
- •Any contraindications to angiography and hepatic artery catheterization such as:
- •History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine that cannot be corrected or premedicated
- •Bleeding diathesis, not correctable by usual forms of therapy
- •Severe peripheral vascular disease that would preclude catheterization
- •Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs in a single treatment
- •Evidence of pulmonary insufficiency
- •Evidence of any detectable technetium-99m macroaggregated serum albumin (Tc-99m MAA) flow to the stomach or duodenum, not correctable by using established angiographic techniques to stop or mitigate such flow
- •Significant extrahepatic disease representing an imminent life-threatening outcome
- •Active uncontrolled infection
- •Significant underlying medical or psychiatric illness
- •Co-morbid disease of condition that would preclude safe delivery of TheraSphere treatment or, in the judgment of the physician, place the patient at undue risk
- •Pregnancy
研究组 & 干预措施
Treatment (yttrium Y 90 glass microspheres)
Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
干预措施: yttrium Y 90 glass microspheres (Radiation)
Treatment (yttrium Y 90 glass microspheres)
Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
干预措施: laboratory biomarker analysis (Other)
Treatment (yttrium Y 90 glass microspheres)
Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
干预措施: TheraSphere (Drug)
结局指标
主要结局
Response to treatment
时间窗: Up to 2 years
Survival time
时间窗: Up to 2 years
Adverse experiences
时间窗: Up to 2 years
次要结局
未报告次要终点
研究者
Ali Rikabi
Principal Investigator
Ohio State University Comprehensive Cancer Center